Last updated: 2026-09-06 11:49:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Xilio Therapeutics, Inc. (XLO) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9.05, with a market capitalization of $58.17M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $6.47 to $12.74. This page covers its latest market performance, valuation, price trends and company information.
$58.17M | |
$9.34 | |
$391.30 | |
$6.47 | |
$9.02 | |
7.43K | |
-- | |
-- | |
$12.74 | |
$6.47 | |
-- | |
-- |
Xilio Therapeutics, Inc. (XLO) last closed at $9.02 as of 2026-09-04 23:31:00, unchanged from the previous close of $9.02.
During the latest regular trading session, XLO traded between $6.47 and $391.30, with a volume of 7.43K shares. The closing price was near the lower end and near the middle of its 52-week range.
Over the past seven days, Xilio Therapeutics, Inc. (XLO) moved from $9.00 to $9.05, representing a gain of 0.51% ($0.05).
The stock traded between $8.82 and $9.34 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 11.04 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 41.1%
XLO is currently trading at $9.05, placing it 41.1% of the way from its 52-week low of $6.47 to its 52-week high of $12.74. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 76 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Xilio Therapeutics, Inc. (XLO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.